Skip to main content

Explore our strategy and projects
to learn about the future of our company

Results FY 2024 (€/MLN)

1,185

Revenues

394

Adjusted EBITDA

236

Adjusted net profit

241

Free cash flow

Stock price

Discover more

Press releases

07/06/25 - 12:25

Diasorin announces 510(k) clearance for LIAISON PLEX® Gram-Positive Blood Culture Assay, to complete the Blood Culture portfolio on LIAISON PLEX®

06/05/25 - 17:41

Price sensitive
Revenue growing +8% and EBITDA margin at 34%: Q1 Results confirm FY 2025 Guidance
Learn More

Presentations

06/05/25

Q1 2025 Results Presentation
Learn More
Presentations
Calendar

LIAISON PLEX® System: the new multiplexing platform of the Group

Diasorin's LIAISON PLEX® System and Respiratory Flex Assay Revolutionize Diagnostics with Flexibility and have Earned FDA Clearance.

Liaison Plex

Keep
in touch

Sign up for our investor alerts
and stay informed
on the latest developments

Privacy Statement *
The Undersigned Confirms That The Information. Provided Pursuant To Leg. Decree No. 196/2003 Has Been Read And Accepted.